Recent advances and prospects of axial spondyloarthritis / ankylosing spondylitis treatment
https://doi.org/10.14412/1996-7012-2021-2-94-105
Abstract
Well-established and some little-known treatments of axial spondyloarthritis / ankylosing spondylitis (AS), which have appeared in recent years are discussed, also discussed are emerging trends for AS treatment.
About the Author
Sh. F. Erdes
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
Shandor Fedorovich Erdes
34A, Kashirskoe shosse, Moscow115522
References
1. Erdes ShF, Rebrov AP, Dubinina TV, et al. Spondyloarthritis: modern terminology and definitions. Terapevticheskii arkhiv. 2019; 91(5):84-8. (In Russ.).
2. Van der Heijde D, Ramiro S, LandewО R, et al. 2016 update of the ASAS/EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017 Jun;76(6): 978-91. doi: 10.1136/annrheumdis-2016-210770. Epub 2017 Jan 13.
3. Lubrano E, D'Angelo S, Spadaro A, et al. Rehabilitation for ankylosing spondylitis in the era of biologics: any room left for this treatment? J Rheumatol. 2011 Jul;38(7): 1228-30. doi: 10.3899/jrheum.110362.
4. Hilberdink B, van der Giesen F, VlietVlieland T, et al. Supervised group exercise in axial spondyloarthritis: patients' satisfaction and perspective on evidence-based enhancements. Arthritis Care Res (Hoboken). 2020 Jun;72(6):829-37. doi: 10.1002/acr.23892. Epub 2020 Apr 25.
5. Liang H, Xu L, Tian X, et al. The comparative efficacy of supervised- versus home-based exercise programs in patients with ankylosing spondylitis: A meta-analysis. Medicine (Baltimore). 2020 Feb;99(8):e19229. doi: 10.1097/MD.0000000000019229.
6. Perrotta FM, Musto A, Lubrano E. New Insights in Physical Therapy and Rehabilitation in Axial Spondyloarthritis: A Review. Rheumatol Ther. 2019 Dec;6(4): 479-86. doi: 10.1007/s40744-019-00170-x. Epub 2019 Aug 13.
7. Zao1 A, Cantista P. The role of land and aquatic exercise in ankylosing spondylitis: a systematic review. Rheumatol Int. 2017 Dec; 37(12):1979-90. doi: 10.1007/s00296-017-3829-8. Epub 2017 Oct 5.
8. Sveaas SH, Berg IJ, Fongen C, et al. Highintensity cardiorespiratory and strength exercises reduced emotional distress and fatigue in patients with axial spondyloarthritis: A randomized controlled pilot study. Scand J Rheumatol. 2018 Mar;47(2):117-21. doi: 10.1080/03009742.2017.1347276. Epub 2017 Sep 11.
9. Sveaas SH, Bilberg A, Berg IJ, et al. High intensity exercise for 3 months reduces disease activity in axial spondyloarthritis (axSpA): a multicentre randomised trial of 100 patients. Br J Sports Med. 2020 Mar; 54(5):292-7. doi: 10.1136/bjsports-2018-099943. Epub 2019 Feb 11.
10. Escalas C, Dalichampt M, Dougados M, Poiraudeau S. Evaluation of physiotherapy in a prospective cohort of early axial spondyloarthritis. Data from the DESIR cohort. Joint Bone Spine. 2016 Mar;83(2):185-90. doi: 10.1016/j.jbspin.2015.05.008. Epub 2015 Dec 8.
11. Husakova M, Siebuhr AS, Pavelka K, et al. Changes of patient-reported outcomes and protein fingerprint biomarkers after exercise therapy for axial spondyloarthritis. Clin Rheumatol. 2019 Jan;38(1):173-9. doi: 10.1007/s10067-017-3802-7. Epub 2017 Aug 30.
12. Cozzi F, Galozzi P, Ciprian L, et al. Mud-bath treatment of seronegative spondyloarthritis: experience at the Euganean Thermal Area. Int J Biometeorol. 2020 Jun; 64(6):937-41. doi: 10.1007/s00484-019-01761-7. Epub 2019 Jul 24.
13. Xuan Y, Huang H, Huang Y, et al. The Efficacy and Safety of Simple-Needling Therapy for Treating Ankylosing Spondylitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Evid Based Complement Alternat Med. 2020 Jun 13;2020: 4276380. doi: 10.1155/2020/4276380. eCollection 2020.
14. Sukhareva ML, Dubinina TV, Erdes ShF, Agasarov LG. Problems of applying the principles of evidence-based medicine in the medical rehabilitation of rheumatic diseases. Nauchno-prakticheskaya revmatologiya. 2015; 53(5):564-7. (In Russ.).
15. Karateev AE, Sukhareva MV, Lila AM. Medical rehabilitation in the complex treatment of rheumatic diseases: a review of the literature data. Nauchno-prakticheskaya revmatologiya. 2019;57(5):584-96. (In Russ.).
16. Wong-Rieger D. Moving from patient advocacy to partnership: a long and bumpy road. Patient. 2017 Jun;10(3):271-6. doi: 10.1007/s40271-017-0216-1.
17. Gaidukova IZ, Rebrov AP, Otteva EN, et al. Use of nonsteroidal anti-inflammatory drugs for the treatment of axial spondyloarthritis, including ankylosing spondylitis, monitoring of efficacy and safety (draft recommendations of the expert group on the diagnosis and treatment of spondyloarthritis). Nauchnoprakticheskaya revmatologiya. 2016;54(Suppl. 1) :67-74. (In Russ.).
18. Lapshina SA, Dubinina TV, Badokin VV, et al. Tumor necrosis factor α inhibitors in the treatment of axial spondyloarthritis, including ankylosing spondylitis. Nauchnoprakticheskaya revmatologiya. 2016;54 (Suppl. 1):75-9. (In Russ.).
19. Dubinina TV, Gaidukova IZ, Godzenko AA, et al. Recommendations for assessing the activity of the disease and the functional state of patients with ankylosing spondylitis in clinical practice. Nauchno-prakticheskaya revmatologiya. 2017;55(4):344-50. (In Russ.).
20. Gaidukova IZ, Rebrov AP, Lapshina SA, et al. The use of nonsteroidal anti-inflammatory drugs and genetically engineered biological drugs for the treatment of axial spondyloarthritis. Recommendations of the Expert Group on the study of spondyloarthritis at the All-Russian Public Organization «Association of Rheumatologists of Russia». Nauchnoprakticheskaya revmatologiya. 2017;55(5): 474-84. (In Russ.).
21. Sieper J, Rudwaleit M, Baraliakos X, et al. The assessment of spondyloarthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009 Jun;68 Suppl 2:ii1-44. doi: 10.1136/ard.2008.104018.
22. Garrido-Cumbrera M, Chacon-Garcia J, Navarro-Compan V, et al. Does Belonging to a Patient Association Is of Help for Patients with Axial Spondyloarthritis? Results from the Atlas Survey. Curr Rheumatol Rep. 2020 May 14;22(6):22. doi: 10.1007/s11926-020-00897-5.
23. Ji X, Wang Y, Ma Y, et al. Improvement of disease management and cost effectiveness in Chinese patients with ankylosing spondylitis using a smart-phone management system: A prospective cohort study. Biomed Res Int. 2019 Feb 25;2019:2171475. doi: 10.1155/2019/2171475. eCollection 2019.
24. Ji X, Hu L, Wang Y, et al. «Mobile Health» for the Management of Spondyloarthritis and Its Application in China. Curr Rheumatol Rep. 2019 Nov 19; 21(11):61. doi: 10.1007/s11926-019-0860-7.
25. Rumiantceva DG, Lila AM, Erdes S. Remote monitoring of patients with axial spondyloarthritis during the COVID-19 pandemic: results and prospects of using the information technology «ASpine». NauchcnoPracticheskaya Revmatologia. 2020;58(6): 683-90 (In Russ.). doi: 10.47360/1995-4484-2020-683-690
26. Perrotta F, Musto A, Lubrano E. New Insights in Physical Therapy and Rehabilitation in Axial Spondyloarthritis: A Review. Rheumatol Ther. 2019 Dec;6(4): 479-86. doi: 10.1007/s40744-019-00170-x. Epub 2019 Aug 13.
27. Van der Heijde D, Ramiro S, Landew О R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017 Jun; 76(6):978-91. doi: 10.1136/annrheumdis2016-210770. Epub 2017 Jan 13.
28. Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Care Res (Hoboken). 2019 Oct; 71(10):1285-99. doi: 10.1002/acr.24025. Epub 2019 Aug 21.
29. Kroon F, Burg L, Ramiro S, et al. Non-steroidal anti-inflammatory drugs in axial spondyloarthritis: a Cochrane review. J Rheumatol. 2016 Mar;43(3):607-17. doi: 10.3899/jrheum.150721. Epub 2016 Feb 1.
30. Tang M, Xue L, Shen Y, et al. Efficacy of long-term nonsteroidal antiinflammatory drug treatment on magnetic resonance imaging-determined bone marrow oedema in early, active axial spondyloarthritis patients. Clin Rheumatol. 2018 Jan;37(1):245-50. doi: 10.1007/s10067-017-3666-x. Epub 2017 May 11.
31. Balazcs E, van der Heijde D, Narinder R, et al. A randomized, clinical trial to assess the relative efficacy and tolerability of two doses of etoricoxib in patients with ankylosing spondylitis. Clin Rheumatol. 2018 Jan;37(1): 245-50. doi: 10.1007/s10067-017-3666-x. Epub 2017 May 11.
32. Huang F, Gu J, Liu Y, et al. Efficacy and safety of celecoxib in Chinese patients with ankylosing spondylitis: a 6-week randomized, double-blinded study with 6-week open-label extension treatment. Curr Ther Res Clin Exp. 2014 Dec 5;76:126-33. doi: 10.1016/j.curtheres.2014.08.002. eCollection
33. Wanders A, van der Heijde D, Landewе R, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: A randomized clinical trial. Arthritis Rheum. 2005 Jun;52(6):1756-65. doi: 10.1002/art.21054.
34. Kroon F, Landewe R, Dougados M, et al. Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Ann Rheum Dis. 2012 Oct;71(10):1623-9. doi: 10.1136/annrheumdis-2012-201370. Epub 2012 Apr 24.
35. Sieper J, Listing J, Poddubnyy D, et al. Effect of continuous versus ondemand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: Results from a randomised multicenter trial (ENRADAS). Ann Rheum Dis. 2016 Aug;75(8):1438-43. doi: 10.1136/annrheumdis-2015-207897. Epub 2015 Aug 4.
36. Poddubnyy D, Rudwaleit M, Haibel H, et al. Effect of non-steroidal antiinяammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: Results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis. 2012 Oct;71(10): 1616-22. doi: 10.1136/annrheumdis-2011-201252. Epub 2012 Mar 29.
37. Erdes Sh, Rumyantseva DG, Smirnov AV, Dubinina TV. Disease activity and two-year dynamics of changes in the sacroiliac joints according to instrumental research methods in patients with early axial spondyloarthritis of the CORSAIR cohort. Nauchno-prakticheskaya revmatologiya. 2019;57(2):186-90. (In Russ.).
38. Bochkova AG. The role of glucocorticoids in the treatment of spondyloarthritis. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2011;5(1):76-9. (In Russ.). doi: https://doi.org/10.14412/1996-7012-2011-656
39. Maugars Y, Mathis C, Berthelot JM, et al. Assessment of the efficacy of sacroiliac corticosteroid injections in spondylarthropathies: a double-blind study. Br J Rheumatol. 1996 Aug;35(8):767-70. doi: 10.1093/rheumatology/35.8.767.
40. Luukkainen R, Nissilä M, Asikainen E, et al. Periarticular corticosteroid treatment of the sacroiliac joint in patients with seronegative spondylarthropathy. Clin Exp Rheumatol. Jan-Feb 1999;17(1):88-90.
41. Wendling D. Local sacroiliac injections in the treatment of spondyloarthritis. What is the evidence? Joint Bone Spine. 2020 May; 87(3):209-13. doi: 10.1016/j.jbspin.2019.06.003. Epub 2019 Jun 16.
42. Haibel H, Fendler C, Listing J, et al. Efficacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomised, placebo-controlled short-term trial. Ann Rheum Dis. 2014 Jan;73(1):243-6. doi: 10.1136/annrheumdis-2012-203055. Epub 2013 Apr 26.
43. Van der Heijde D, Deodhar A, Wei JC, et al. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis. 2017 Aug;76(8):1340-47. doi: 10.1136/annrheumdis-2016-210322. Epub 2017 Jan 27.
44. Van der Heijde D, Baraliakos X, Gensler LS, et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. Lancet. 2018 Dec 1; 392(10162):2378-87. doi: 10.1016/S0140-6736(18)32463-2. Epub 2018 Oct 22.
45. Van der Heijde D, Song IH, Pangan AL, et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. Lancet. 2019 Dec 7;394(10214): 2108-17. doi: 10.1016/S0140-6736(19)32534-6. Epub 2019 Nov 12.
46. Nash P, Kerschbaumer A, Dö rner T, et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Ann Rheum Dis. 2021 Jan;80(1): 71-87. doi: 10.1136/annrheumdis-2020-218398.
47. Baraliakos X, Witte T, De Clerck L, et al. Effectiveness and safety of 12-month certolizumabpegol treatment for axial spondyloarthritis in real-world clinical practice in Europe. Rheumatology (Oxford). 2020 Jun 25: keaa181. doi: 10.1093/rheumatology/keaa181. Epub ahead of print.
48. Manica1 SR ,Sepriano A, PimentelSantos F, et al. Effectiveness of switching between TNF inhibitors in patients with axial spondyloarthritis: is the reason to switch relevant? Arthritis Res Ther. 2020 Aug 21;22(1): 195. doi: 10.1186/s13075-020-02288-8.
49. Baraliakos X, Listing J, Rudwaleit M, et al. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab. Ann Rheum Dis. 2005 Oct;64(10):1462-6. doi: 10.1136/ard.2004.033472. Epub 2005 Mar 18.
50. Baraliakos X, Listing J, Brandt J, et al. Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab. Rheumatology (Oxford). 2007 Sep;46(9): 1450-3. doi: 10.1093/rheumatology/kem166. Epub 2007 Jul 10.
51. Haroon N, Inman RD, Learch TJ, et al. The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum. 2013 Oct;65(10):2645-54. doi: 10.1002/art.38070.
52. Baraliakos X, Haibel H, Listing J, et al. Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. Ann Rheum Dis. 2014 Apr;73(4):710-5. doi: 10.1136/annrheumdis2012-202698. Epub 2013 Mar 16.
53. Pedersen SJ, Weber U, Said-Nahal R, et al. Structural progression rate decreases over time on serial radiography and magnetic resonance imaging of sacroiliac joints and spine in a five-year follow-up study of patients with ankylosing spondylitis treated with tumour necrosis factor inhibitor. Scand J Rheumatol. 2019 May;48(3):185-97. doi: 10.1080/03009742.2018.1506822. Epub 2018 Nov 13.
54. Jeong H, Eun YH, Kim IY, et al. Effect of tumor necrosis factor α inhibitors on spinal radiographic progression in patients with ankylosing spondylitis. Int J Rheum Dis. 2018 May;21(5):1098-1105. doi: 10.1111/1756-185X.13270. Epub 2018 Apr 2.
55. Park JW, Kwon HM, Park JK, et al. Impact of dose tapering of tumor necrosis factor inhibitor on radiographic progression in ankylosing spondylitis. PLoS One. 2016 Dec 29;11(12):e0168958. doi: 10.1371/journal.pone.0168958. eCollection 2016.
56. Molnar C, Scherer A, Baraliakos X, et al. TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort. Ann Rheum Dis. 2018 Jan;77(1):63-9. doi: 10.1136/annrheumdis2017-211544. Epub 2017 Sep 22.
57. Li L, Chen B, Zhao H, Wang G. Bone changes and curative effect of infliximab in patients with ankylosing spondylitis. J Musculoskelet Neuronal Interact. 2020 Sep 1;20(3):437-43.
58. Visvanathan S, van der Heijde D, Deodhar A, et al. Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. Ann Rheum Dis. 2009 Feb;68(2):175-82. doi: 10.1136/ard.2007.084426. Epub 2008 May 21.
59. Wang C, Li W. Effects of etanercept and inяiximab on bone metabolism indexes in patients with ankylosing spondylitis. Exp Ther Med. 2020 Jan;19(1):585-90. doi: 10.3892/etm.2019.8266. Epub 2019 Dec 2.
60. Landewe RB, van der Heijde D, Dougados M, et al. Maintenance of clinical remission in early axial spondyloarthritis following certolizumabpegol dose reduction. Ann Rheum Dis. 2020 Jul;79(7):920-8. doi: 10.1136/annrheumdis-2019-216839. Epub 2020 May 7.
61. Landewe R, van der Heijde D, Dougados M, et al. Induction of Sustained Clinical Remission in Early Axial Spondyloarthritis Following CertolizumabPegol Treatment: 48-Week Outcomes from C-OPTIMISE. Rheumatol Ther. 2020 Sep;7(3):581-99. doi: 10.1007/s40744-020-00214-7.
62. Landewe R, Sieper J, Mease P, et al. Effcacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with nonradiographic axial spondyloarthritis (aBiliTY-3): a multicentre, randomised, doubleblind study. Lancet. 2018 Jul 14;392(10142):134-44. doi: 10.1016/S0140-6736(18)31362-X. Epub 2018 Jun 29.
63. Navarro-Compan V, Plasencia-Rodriguez C, de Miguel E, et al. Anti-Tnf discontinuation and tapering strategies in patients with axial spondyloarthritis: a systematic literature review. Rheumatology (Oxford). 2016 Jul;55(7): 1188-94. doi: 10.1093/rheumatology/kew033. Epub 2016 Mar 21.
64. Almirall M, Salman-Monte TC, Lisbona MP, et al. Dose reduction of biological treatment in patients with axial spondyloarthritis in clinical remission: Are there any differences between patients who relapsed and to those who remained in low disease activity? Rheumatol Int. 2015 Sep;35(9): 1565-8. doi: 10.1007/s00296-015-3288-z. Epub 2015 May 21.
65. Wei JC, Tsou HK, Leong PY, et al. Headto-Head Comparison of Etanercept vs. Adalimumab in the Treatment of Ankylosing Spondylitis: An Open-Label Randomized Controlled Crossover Clinical Trial. Front Med (Lausanne). 2020 Oct 30;7:566160. doi: 10.3389/fmed.2020.566160. eCollection 2020.
66. Lubrano E, Spadaro A, Amato G, et al. Tumour necrosis factor alpha inhibitor therapy and rehabilitation for the treatment of ankylosing spondylitis: a systematic review. Semin Arthritis Rheum. 2015 Apr;44(5): 542-50. doi:10.1016/j.semarthrit.2014.09.012. Epub 2014 Sep 28.
67. Giannotti E, Trainito S, Arioli G, et al. Effects of physical therapy for the management of patients with ankylosing spondylitis in the biological era. Clin Rheumatol. 2014 Sep;33(9):1217-30. doi: 10.1007/s10067-014-2647-6. Epub 2014 May 7.
68. Lubrano E, D'Angelo S, Parsons WJ, et al. Effects of a combination treatment of an intensive rehabilitation program and etanercept in patients with ankylosing spondylitis: a pilot study. J Rheumatol. 2006 Oct;33(10): 2029-34.
69. Godzenko AA, Bochkova AG, Rumyantseva OA, et al. Effect of therapy with tumor necrosis factor α inhibitors on the frequency of uveitis exacerbations in patients with ankylosing spondylitis. Nauchno-prakticheskaya revmatologiya. 2014;52(1):27-30. (In Russ.).
70. Van Bentum RE, Heslinga SC, Nurmohamed MT, et al. Reduced Occurrence Rate of Acute Anterior Uveitis in Ankylosing Spondylitis Treated with Golimumab – The GO-EASY Study. J Rheumatol. 2019 Feb;46(2):153-9. doi: 10.3899/jrheum.180312. Epub 2018 Nov 1.
71. Zurita Prada PA, Urrego Laurin CL, Guillen Astete CA, et al. Influence of smoking and obesity on treatment response in patients with axial spondyloarthritis: a systematic literature review. Clin Rheumatol. 2020 Sep 3. doi: 10.1007/s10067-020-05319-6. Online ahead of print.
72. Goll GL, Haavardsholm EA, Kvien TK. The confidence of rheumatologists about switching to biosimilars for their patients. Joint Bone Spine. 2018 Oct;85(5):507-9. doi: 10.1016/j.jbspin.2018.03.009. Epub 2018 Apr 6.
73. Lindström U, Glintborg B, Di Giuseppe D, et al. Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naive patients with spondyloarthritis. RMD Open. 2019 Oct 23;5(2):e001079. doi: 10.1136/rmdopen2019-001079.
74. Tweehuysen L, Huiskes VJB, van den Bemt BJF, et al. Open-Label, NonMandatory Transitioning From Originator Etanercept to Biosimilar SB4: Six-Month Results From a Controlled Cohort Study. Arthritis Rheumatol. 2018 Sep;70(9):1408-18. doi: 10.1002/art.40516. Epub 2018 Aug 6.
75. Ditto MC, Parisi S, Priora M, et al. Efficacy and safety of a single switch from etanercept originator to etanercept biosimilar in a cohort of inflammatory arthritis. Sci Rep. 2020 Sep 30;10(1):16178. doi: 10.1038/s41598-020-73183-0.
76. Gerdes S, Thaci D, Griffiths CEM, et al. Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study. J Eur Acad Dermatol Venereol. 2018 Mar;32(3):420-7. doi: 10.1111/jdv.14605. Epub 2017 Nov 2.
77. Li KP, Jin JY, Yang JS, et al. Full dose, half dose, or discontinuation of etanercept biosimilar in early axial spondyloarthritis patients: a real-world study in China. Arch Med Sci. 2019 May;15(3):700-5. doi: 10.5114/aoms.2018.76141. Epub 2018 Jun 1.
78. Vesely R, Richardson P. The switch to infliximab biosimilars. Lancet. 2017 Jun 10; 389(10086):2266-8. doi: 10.1016/S0140-6736(17)31258-8. Epub 2017 May 11.
79. J∅rgensen KK, Olsen IC, Goll GL, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017 Jun 10;389(10086):2304-16. doi: 10.1016/S0140-6736(17)30068-5. Epub 2017 May 11.
80. Gonzalez-Fernandez M, Villamanan E, Jimenez-Nacher I, et al. Cost evolution of biological agents for the treatment of spondyloarthritis in a tertiary hospital: influential factors in price. Int J Clin Pharm. 2018 Dec; 40(6):1528-38. doi: 10.1007/s11096-018-0703-z.
81. Valido A, Silva-Dinis J, Saavedra MJ, et al. Efficacy, immunogenicity and cost analysis of a systematic switch from originator infliximab to biosimilar CT-P13 of all patients with inflammatory arthritis from a single center. Acta Reumatol Port. Oct-Dec 2019;44(4):303-11.
82. Glintborg B, Ibsen R, Bilbo REQ, et al. Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs? A Danish register-based study of patients with inflammatory arthritis. RMD Open. 2019 Aug 12; 5(2):e001016. doi: 10.1136/rmdopen-2019-001016.
83. Yin Y, Wang M, Liu M, et al. Efficacy and safety of IL-17 inhibitors for the treatment of ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Res Ther. 2020 May 12;22(1):111. doi: 10.1186/s13075-020-02208-w.
84. Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015 Dec 24;373(26):2534-48. doi: 10.1056/NEJMoa1505066.
85. Pavelka K, Kivitz A, Dokoupilova E, et al. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. Arthritis Res Ther. 2017 Dec 22;19(1):285. doi: 10.1186/s13075-017-1490-y.
86. Kivitz AJ, Wagner U, Dokoupilova E, et al. Efficacy and safety of secukinumab 150 mg with and without loading regimen in ankylosing spondylitis: 104-week results from MEASURE 4 study. Rheumatol Ther. 2018 Dec;5(2):447-62. doi: 10.1007/s40744-018-0123-5. Epub 2018 Aug 18.
87. Van der Heijde D, Cheng-Chung Wei J, Dougados M, et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological diseasemodifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, doubleblind, active-controlled and placebo-controlled trial. Lancet. 2018 Dec 8; 392(10163):2441-51. doi: 10.1016/S0140-6736(18)31946-9. Epub 2018 Oct 22.
88. Braun J, Deodhar A, Landewe R, et al. Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies. RMD Open. 2018 Nov 21; 4(2):e000749. doi: 10.1136/rmdopen-2018-000749. eCollection 2018.
89. Braun J, Baraliakos X, Deodhar A, et al. Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study. Rheumatology (Oxford). 2019 May 1;58(5):859-68. doi: 10.1093/rheumatology/key375.
90. Deodhar AA, Miceli-Richard C, Baraliakos X, et al. Incidence of Uveitis in Secukinumab-treated Patients With Ankylosing Spondylitis: Pooled Data Analysis From Three Phase 3 Studies. ACR Open Rheumatol. 2020 May;2(5):294-9. doi: 10.1002/acr2.11139.
91. Nadwi H, Janaini M, Zammo M, et al. New-Onset Uveitis Possibly Caused by Secukinumab in a 47-Year-Old Male Patient with Long-Standing Ankylosing Spondylitis. Int Med Case Rep J. 2020 Aug 5;13:331-4. doi: 10.2147/IMCRJ.S265812.
92. Baraliakos X, ∅stergaard M, Gensler LS, et al. Comparison of the Effects of Secukinumab and Adalimumab Biosimilar on Radiographic Progression in Patients with Ankylosing Spondylitis: Design of a Randomized, Phase IIIb Study (SURPASS). Clin Drug Investig. 2020 Mar;40(3):269-78. doi: 10.1007/s40261-020-00886-7.
93. Dougados M, Cheng-Chung Wei JCC, LandewО R, et al. Effcacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). Ann Rheum Dis. 2020 Feb;79(2):176-85. doi: 10.1136/annrheumdis-2019-216118.
94. Marzo-Ortega H, Mease PJ, Rahman P, et al. Impact of Ixekizumab on Work Productivity in Patients with Ankylosing Spondylitis: Results from the COAST-V and COAST-W Trials at 52 Weeks. Rheumatol Ther. 2020 Dec;7(4):759-74. doi: 10.1007/s40744-020-00225-4. Epub 2020 Aug 19.
95. Erdes S, Nasonov E, Kunder E, et al. Primary effcacy of netakimab, a novel interleukin-17 inhibitor, in the treatment of active ankylosing spondylitis in adults. Clin Exp Rheumatol. Jan-Feb 2020;38(1):27-34. Epub 2019 Apr 16.
96. Mazurov VI, Erdes ShF, Gaidukova IZ, et al. Long-term efficacy and safety of netakimab in the treatment of ankylosing spondylitis: results of Phase III international, multicenter, randomized double-blind clinical trial BCD085-5/ASTERA. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2020;14(4): 39-49. (In Russ.). doi: 10.14412/1996-7012-2020-4-39-49
97. Van der Heijde D, Gensler LS, Deodhar A, et al. Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study. Ann Rheum Dis. 2020 May; 79(5):595-604. doi: 10.1136/annrheumdis2020-216980. Epub 2020 Apr 6.
98. Glatt S, Baeten D, Baker T, et al. Dual il-17a and il-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that il-17F contributes to human chronic tissue inflammation. Ann Rheum Dis. 2018 Apr;77(4):523- 32. doi: 10.1136/annrheumdis-2017-212127. Epub 2017 Dec 23.
99. Ammari M, Presumey J, Ponsolles C, et al. Delivery of miR-146a to ly6C(high) monocytes inhibits pathogenic bone erosion in inflammatory arthritis. Theranostics. 2018 Nov 13;8(21):5972-85. doi: 10.7150/thno.29313. eCollection 2018.
100. Shah M, Maroof A, al-Hosni RN, et al. Bimekizumab blocks T cell-mediated osteogenic differentiation of periosteal stem cells: coupling pathological bone formation to il-17a and il-17F signaling [abstract]. Arthritis Rheumatol 2017;69 (suppl 10):1936.
101. Gracey E, Yao Y, Green B, et al. Sexual dimorphism in the Th17 signature of ankylosing spondylitis. Arthritis Rheumatol. 2016 Mar; 68(3):679-89. doi: 10.1002/art.39464.
102. Poddubnyy D, Vicari A, Haibel H, et al. Interleukin-17 serum levels are associated with markers of systemic inяammation in patients with active ankylosing spondylitis [abstract]. ACR/ARHP Annual Meeting; 2013.
103. Elewski B, Rich P, Lain E, et al. Efficacy of brodalumab in the treatment of scalp and nail psoriasis: results from three phase 3 trials. J Dermatolog Treat. 2020 Apr 21:1-5. doi: 10.1080/09546634.2020.1749546. Epub ahead of print.
104. Facheris P, Valenti M, Pavia G, et al. Brodalumab: A new way to inhibit IL-17 in psoriasis. Dermatol Ther. 2020 May;33(3): e13403. doi: 10.1111/dth.13403. Epub 2020 Apr 27.
105. Baraliakos X, Gensler LS, D'Angelo S, et al. Biologic therapy and spinal radiographic progression in patients with axial spondyloarthritis: A structured literature review. Ther Adv Musculoskelet Dis. 2020 Mar 4;12: 1759720X20906040. doi: 10.1177/1759720X20906040.
106. Deodhar A, Gensler LS, Sieper J, et al. Three multicenter, randomized, double-blind Placebo-controlled studies evaluating the efficacy and safety of Ustekinumab in axial spondyloarthritis. Arthritis Rheumatol. 2019 Feb;71(2):258-70. doi: 10.1002/art.40728. Epub 2018 Dec 29.
107. Baeten D, ∅stergaard M, Wei JCC, et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-ofconcept, dose-finding phase 2 study. Ann Rheum Dis. 2018 Sep;77(9):1295-1302. doi: 10.1136/annrheumdis-2018-213328. Epub 2018 Jun 26.
108. Pathan E, Abraham S, van Rossen E, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis. Ann Rheum Dis. 2013 Sep 1; 72(9):1475-80. doi: 10.1136/annrheumdis2012-201915. Epub 2012 Sep 14.
109. Haibel H, Rudwaleit M, Listing J, Sieper J. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis. 2005 Feb;64(2):296-8. doi: 10.1136/ard.2004.023176. Epub 2004 Jun 18.
110. Sieper J, Porter-Brown B, Thompson L, et al. Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebocontrolled trials. Ann Rheum Dis. 2014 Jan; 73(1):95-100. doi: 10.1136/annrheumdis2013-203559.
111. Rumyantseva DG, Agafonova EM, Urumova MM, et al. Results of the use of an interleukin 6 inhibitor in ankylosing spondylitis (AS). Nauchno-prakticheskaya revmatologiya. 2020;58(5):615. (In Russ.).
112. Song IH, Heldmann F, Rudwaleit M, et al. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum. 2010 May;62(5):1290-7. doi: 10.1002/art.27383.
113. Protopopov MS, Erdes ShF, Lapshina SA, et al. Comparison of the effect of rituximab, tumor necrosis factor alpha inhibitors, and nonsteroidal anti-inflammatory drugs on the activity of ankylosing spondylitis and the severity of sacroiliitis according to magnetic resonance imaging. Kazanskii Meditsinskii Zhurnal. 2013;(6):870-6. (In Russ.).
114. Song IH, Heldmann F, Rudwaleit M, et al. Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. Ann Rheum Dis. 2011 Jun;70(6):1108-10. doi: 10.1136/ard.2010.145946.
115. Mease PJ, Genovese MC, Weinblatt M, et al. Safety and efficacy of ABT-122, a TNF and IL-17-Targeted Dual Variable Domain (DVD)-Ig™, in Psoriatic Arthritis Patients with Inadequate Response to Methotrexate: Results from a Phase 2 Trial [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/safety-andefficacy-of-abt-122-a-tnf-and-il-17-targeteddual-variable-domain-dvd-ig-in-psoriaticarthritis-patients-with-inadequate-responseto-methotrexate-results-from/. Accessed February 25, 2021.
116. Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis? Ann Rheum Dis. 2018 Feb;77(2):175-87. doi: 10.1136/annrheumdis-2017-211555. Epub 2017 Aug 1.
117. Huang F, Gu J, Zhao W, et al. One-year open-label trial of thalidomide in ankylosing spondylitis. Arthritis Rheum. 2002 Jun 15; 47(3):249-54. doi: 10.1002/art.10396.
118. Wei JCC, Chan NW, Lin HS, et al. Thalidomide for severe refractory ankylosing spondylitis: a 6-month open-label trial. J Rheumatol. 2003 Dec;30(12):2627-31.
119. Man S, Ji X, Wang Y, et al. Add-On Effects of Conventional Synthetic DiseaseModifying Anti-Rheumatic Drugs in Ankylosing Spondylitis: Data from a RealWorld Registered Study in China. Med SciMonit. 2020 Jan 21;26:e921055. doi: 10.12659/MSM.921055.
120. Paramarta JE, Turina MC, Noordenbos T, et al. A proof-of-concept study with the tyrosine kinase inhibitor nilotinib in spondyloarthritis. J Transl Med. 2016 Oct 27; 14(1):308. doi: 10.1186/s12967-016-1050-2.
121. Luo Y, Zheng N, Wu R. Is iguratimod effective in refractory axial spondyloarthritis? Scand J Rheumatol. 2018 Nov;47(6):518-20. doi: 10.1080/03009742.2017.1390150. Epub 2018 Feb 7.
122. Huang BJ, Ma JX. Observation of shortterm efficacy of iguratimod in the treatment of ankylosing spondylitis. Chin Commun Doctors. 2018; 34(13):92-3.
123. Xu BJ, Mo XQ, Xue XQ, Wu Y. Study of the efficacy and safety of iguratimod in the treatment of ankylosing spondylitis. J New Med; 2019, 50(12):915-8.
124. Liu S, Cui Y, Zhang X. Molecular mechanisms and clinical studies of iguratimod for the treatment of ankylosing spondylitis. Clin Rheumatol. 2021 Jan;40(1):25-32. doi: 10.1007/s10067-020-05207-z. Epub 2020 Jun 6.
125. Jiang H, Gao H, Wang Q, et al. Molecular mechanisms and clinical application of Iguratimod: A review. Biomed Pharmacother. 2020 Feb;122:109704. doi: 10.1016/j.biopha.2019.109704. Epub 2019 Dec 30.
126. Ranganathan V, Ciccia F, Zeng F, et al. Macrophage Migration Inhibitory Factor Induces Inflammation and Predicts Spinal Progression in Ankylosing Spondylitis. Arthritis Rheumatol. 2017 Sep;69(9): 1796-1806. doi: 10.1002/art.40175.
127. Baerlecken NT, Nothdorft S, Stummvoll GH, et al. Autoantibodies against CD74 in spondyloarthritis. Ann Rheum Dis. 2014 Jun;73(6):1211-4. doi: 10.1136/annrheumdis2012-202208.
128. Jacquin C, Koczon-Jaremko B, Aguila HL, et al. Macrophage migration inhibitory factor inhibits osteoclastogenesis. Bone. 2009 Oct; 45(4):640-9. doi: 10.1016/j.bone.2009.06.028.
129. Ranganathan V, Ciccia F, Zeng F, et al. Macrophage Migration Inhibitory Factor Induces Inflammation and Predicts Spinal Progression in Ankylosing Spondylitis. Arthritis Rheumatol. 2017 Sep;69(9): 1796-1806. doi: 10.1002/art.40175.
130. Kok T, Wasiel AA, Cool RH, et al. Small-molecule inhibitors of macrophage migration inhibitory factor (MIF) as an emerging class of therapeutics for immune disorders. Drug Discov Today. 2018 Nov;23(11): 1910-8. doi: 10.1016/j.drudis.2018.06.017.
131. Al-Mossawi MH, Chen L, Fang H, et al. Unique transcriptome signatures and GM-CSF expression in lymphocytes from patients with spondyloarthritis. Nat Commun. 2017 Nov 15; 8(1):1510. doi: 10.1038/s41467-017-01771-2.
132. Cook AD, Louis C, Robinson MJ, et al. Granulocyte macrophage colony-stimulating factor receptor α expression and its targeting in antigen-induced arthritis and inflammation. Arthritis Res Ther. 2016 Dec 1;18(1):287. doi: 10.1186/s13075-016-1185-9.
133. Van Nieuwenhuijze AE, van de Loo FA, Walgreen B, et al. Complementary action of granulocyte macrophage colony-stimulating factor and interleukin-17A induces interleukin-23, receptor activator of nuclear factor-κB ligand, and matrix metalloproteinases and drives bone and cartilage pathology in experimental arthritis: rationale for combination therapy in rheumatoid arthritis. Arthritis Res Ther. 2015 Jun 17;17(1):163. doi: 10.1186/s13075-015-0683-5.
134. Shiomi A, Usui T, Ishikawa Y, et al. GM-CSF but not IL-17 is critical for the development of severe interstitial lung disease in SKG mice. J Immunol. 2014 Jul 15; 193(2):849-59. doi: 10.4049/jimmunol.1303255.
135. Crotti C, Biggioggero M, Becciolini A, et al. Mavrilimumab: a unique insight and update on the current status in the treatment of rheumatoid arthritis. Expert OpinInvestig Drugs. 2019 Jul;28(7):573-81. doi: 10.1080/13543784.2019.1631795.
136. Hammitzsch A, Tallant C, Fedorov O, et al. CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses. Proc Natl Acad Sci U S A. 2015 Aug 25;112(34):10768-73. doi: 10.1073/pnas.1501956112.
137. Leone G, Fini M, Torricelli P, et al. An amidatedcarboxymethylcellulose hydrogel for cartilage regeneration. J Mater Sci Mater Med. 2008 Aug;19(8):2873-80. doi: 10.1007/s10856-008-3412-7. Epub 2008 Mar 18.
138. Xi Y, Jiang T, Chaurasiya B, et al. Advances in nanomedicine for the treatment of ankylosing spondylitis. Int J Nanomedicine. 2019 Oct 29;14:8521-42. doi: 10.2147/IJN.S216199.
Review
For citations:
Erdes SF. Recent advances and prospects of axial spondyloarthritis / ankylosing spondylitis treatment. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2021;15(2):94-105. (In Russ.) https://doi.org/10.14412/1996-7012-2021-2-94-105
Views:
1492
Email this article 